We also sought factors predictive with KS progression during HAART, analysed the outcome of KS according to CD4 cell count and HIV-1 plasma viral load variations, and compared the benefits of PI and non-PI-based regimens on KS in a subgroup of patients who had not previously received antiretroviral drugs. The gene discussed is CD4; the disease is Kaposi's sarcoma.